Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» biosimilars
biosimilars
Amgen's denosumab shows promise in small, NIH-funded rare bone disease study
Endpoints
Wed, 04/5/23 - 07:15 pm
Amgen
Prolia
Xgeva
denosumab
clinical trials
NIH
biosimilars
monoclonal antibodies
Acquired patents aid J&J defense of top-selling drug from biosimilar challenge
BioPharma Dive
Wed, 03/29/23 - 03:56 pm
Amgen
JNJ
Stelara
psoriasis
patents
biosimilars
J&J finalizes $25M settlement, laying Remicade antitrust allegations to rest
Endpoints
Mon, 03/20/23 - 09:50 am
JNJ
legal
Remicade
antitrust
biosimilars
Sandoz, betting on biosimilar sales, to build new production plant
BioPharma Dive
Thu, 03/9/23 - 09:15 pm
Sandoz
Novartis
drug manufacturing
Slovenia
biosimilars
Citing J&J's 'failure to comply' with court rules, judge nixes early bid to block Amgen's Stelara biosim
Fierce Pharma
Fri, 03/3/23 - 11:56 am
JNJ
patents
Janssen
Amgen
biosimilars
Stelara
Could This Humira Biosimilar Be a Winner for Amgen?
Motley Fool
Fri, 03/3/23 - 11:48 am
Amgen
biosimilars
Amjevita
Humira
Doctors largely comfortable with biosimilar drugs, but question economics: report
BioPharma Dive
Wed, 02/22/23 - 06:49 pm
Cardinal Health
physicians
biosimilars
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Tue, 02/21/23 - 11:05 am
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Pharmaceutical Business Review
Fri, 02/17/23 - 09:44 am
Fresenius Kabi
Stimufend
pegfilgrastim
biosimilars
Neulasta
Amgen
cancer
Years after the first US biosim launches, doctors still have their concerns: survey
Fierce Pharma
Thu, 02/16/23 - 04:49 pm
biosimilars
PBMs
physicians
AbbVie
Humira
Amgen
Amjevita
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
Endpoints
Mon, 02/13/23 - 10:02 pm
FDA
Biocon
Viatris
Avastin
biosimilars
drug manufacturing
AbbVie talks next steps as first Humira competitor makes it to market
Endpoints
Thu, 02/9/23 - 06:01 pm
AbbVie
Humira
biosimilars
Rick Gonzalez
Sandoz files biosimilar of Amgen osteoporosis drug in US
Pharmaphorum
Tue, 02/7/23 - 12:22 pm
Sandoz
Novartis
biosimilars
osteoporosis
Prolia
Xgeva
FDA
Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita
Forbes
Wed, 02/1/23 - 10:41 am
Amgen
Amjevita
AbbVie
Humira
biosimilars
drug pricing
Amgen launches Humira biosimilar, releases Q4 earnings report
Medical Marketing and Media
Tue, 01/31/23 - 11:21 pm
Amgen
Humira
biosimilars
earnings
AbbVie
Amjevita
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
BioPharma Dive
Tue, 01/31/23 - 12:37 pm
AbbVie
Humira
biosimilars
Amgen
The end of the Humira era
EP Vantage
Mon, 01/30/23 - 10:46 am
AbbVie
Humira
patents
biosimilars
Merck
Keytruda
AbbVie Is Set to Lose on Its Biggest Blockbuster. Here's Why You Shouldn't Worry.
Motley Fool
Sun, 01/22/23 - 01:01 pm
AbbVie
Humira
biosimilars
Amgen prepped to take first slice of AbbVie’s US Humira pie
BioProcess International
Wed, 01/18/23 - 11:00 pm
Amgen
Humira
biosimilars
adalimumab
Amjevita
Amgen Boasts Lucrative Acquisitions, Drug Updates, Burgeoning Biosimilars at JPM
BioSpace
Tue, 01/10/23 - 06:43 pm
Amgen
JPMHC 2023
M&A
biosimilars
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »